Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T11451
(Former ID: TTDC00107)
|
|||||
Target Name |
Toll-like receptor 9 (TLR9)
|
|||||
Synonyms |
UNQ5798/PRO19605; TLR-9; CD289
Click to Show/Hide
|
|||||
Gene Name |
TLR9
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Colorectal cancer [ICD-11: 2B91] | |||||
2 | Hepatitis virus infection [ICD-11: 1E50-1E51] | |||||
3 | Melanoma [ICD-11: 2C30] | |||||
4 | Prostate cancer [ICD-11: 2C82] | |||||
Function |
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Controls lymphocyte response to Helicobacter infection. Upon CpG stimulation, induces B-cell proliferation, activation, survival and antibody production.
Click to Show/Hide
|
|||||
BioChemical Class |
Toll-like receptor
|
|||||
UniProt ID | ||||||
Sequence |
MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA
PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFL AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYY KNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDL ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF GSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYV DLSDNRISGASELTATMGEADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDLS RNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHEHS FTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRL RDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAPGF FSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQAA VPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCG WDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRG RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLE DRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHF YNRNFCQGPTAE Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T73ATB |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 27 Clinical Trial Drugs | + | ||||
1 | Cadi-05 | Drug Info | Phase 3 | Prostate cancer | [2] | |
2 | IMO-2125 | Drug Info | Phase 3 | Melanoma | [3], [4] | |
3 | MGN-1703 | Drug Info | Phase 3 | Colorectal cancer | [5] | |
4 | SD-101 | Drug Info | Phase 3 | Hepatitis C virus infection | [6] | |
5 | Tilsotolimod | Drug Info | Phase 3 | Melanoma | [7] | |
6 | BL-7040 | Drug Info | Phase 2 | Inflammatory bowel disease | [8] | |
7 | CpG-10101 | Drug Info | Phase 2 | Hepatitis C virus infection | [9] | |
8 | CYT003 | Drug Info | Phase 2 | Asthma | [10] | |
9 | IMO-2055 | Drug Info | Phase 2 | Solid tumour/cancer | [11] | |
10 | IMO-3100 | Drug Info | Phase 2 | Psoriasis vulgaris | [12] | |
11 | JVRS-100 | Drug Info | Phase 2 | leukaemia | [13] | |
12 | Lefitolimod | Drug Info | Phase 2 | Human immunodeficiency virus-1 infection | [14] | |
13 | MIS-416 | Drug Info | Phase 2 | Autoimmune diabetes | [15] | |
14 | Tolamba | Drug Info | Phase 2 | Allergic rhinitis | [16] | |
15 | Zadaxin/lamivudine | Drug Info | Phase 2 | Hepatitis B virus infection | [17] | |
16 | AST-008 | Drug Info | Phase 1 | Solid tumour/cancer | [3] | |
17 | AZD1419 | Drug Info | Phase 1 | Asthma | [18] | |
18 | Cavrotolimod | Drug Info | Phase 1 | Solid tumour/cancer | [19] | |
19 | CMP-001 | Drug Info | Phase 1 | Melanoma | [3], [4], [20], [21] | |
20 | CPG 52364 | Drug Info | Phase 1 | Systemic lupus erythematosus | [22] | |
21 | DV-1179 | Drug Info | Phase 1 | Autoimmune disease | [23] | |
22 | DV281 | Drug Info | Phase 1 | Non-small-cell lung cancer | [3] | |
23 | GNKG-168 | Drug Info | Phase 1 | Chronic lymphocytic leukaemia | [24] | |
24 | Litenimod | Drug Info | Phase 1 | Glioblastoma multiforme | [25] | |
25 | MGN-1706 | Drug Info | Phase 1 | Solid tumour/cancer | [26] | |
26 | N-8295 | Drug Info | Phase 1 | Influenza virus infection | [27] | |
27 | SAR-21609 | Drug Info | Phase 1 | Asthma | [28] | |
Discontinued Drug(s) | [+] 4 Discontinued Drugs | + | ||||
1 | IR-103 | Drug Info | Discontinued in Phase 3 | Human immunodeficiency virus infection | [29] | |
2 | Agatolimod | Drug Info | Discontinued in Phase 2 | Lung cancer | [30] | |
3 | IM0-8400 | Drug Info | Discontinued in Phase 1/2 | Diffuse large B-cell lymphoma | [31] | |
4 | AVE0675 | Drug Info | Terminated | Asthma | [32] | |
Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | ||||
1 | IMO-2134 | Drug Info | Preclinical | Allergy | [11] | |
Mode of Action | [+] 4 Modes of Action | + | ||||
Agonist | [+] 18 Agonist drugs | + | ||||
1 | IMO-2125 | Drug Info | [11] | |||
2 | MGN-1703 | Drug Info | [34] | |||
3 | Tilsotolimod | Drug Info | [35] | |||
4 | CpG-10101 | Drug Info | [37] | |||
5 | CYT003 | Drug Info | [10] | |||
6 | IMO-2055 | Drug Info | [11] | |||
7 | Lefitolimod | Drug Info | [40] | |||
8 | AST-008 | Drug Info | [3] | |||
9 | AZD1419 | Drug Info | [44] | |||
10 | Cavrotolimod | Drug Info | [45] | |||
11 | CMP-001 | Drug Info | [46] | |||
12 | DV281 | Drug Info | [3] | |||
13 | MGN-1706 | Drug Info | [50] | |||
14 | SAR-21609 | Drug Info | [33] | |||
15 | Agatolimod | Drug Info | [52], [53] | |||
16 | IMO-2134 | Drug Info | [11] | |||
17 | AVE0675 | Drug Info | [55] | |||
18 | COV08-0064 | Drug Info | [56] | |||
Activator | [+] 1 Activator drugs | + | ||||
1 | BL-7040 | Drug Info | [36] | |||
Modulator | [+] 7 Modulator drugs | + | ||||
1 | IMO-3100 | Drug Info | [38] | |||
2 | MIS-416 | Drug Info | [41] | |||
3 | Zadaxin/lamivudine | Drug Info | [43] | |||
4 | DV-1179 | Drug Info | [48] | |||
5 | GNKG-168 | Drug Info | [49] | |||
6 | Litenimod | Drug Info | [50] | |||
7 | DIMS-9054 | Drug Info | [50] | |||
Antagonist | [+] 3 Antagonist drugs | + | ||||
1 | CPG 52364 | Drug Info | [47] | |||
2 | IM0-8400 | Drug Info | [54] | |||
3 | ODN-2088 | Drug Info | [57] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Toll-like receptor signaling pathway | hsa04620 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy |
Degree | 3 | Degree centrality | 3.22E-04 | Betweenness centrality | 1.94E-05 |
---|---|---|---|---|---|
Closeness centrality | 2.03E-01 | Radiality | 1.35E+01 | Clustering coefficient | 3.33E-01 |
Neighborhood connectivity | 2.40E+01 | Topological coefficient | 3.94E-01 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 7 KEGG Pathways | + | ||||
1 | Toll-like receptor signaling pathway | |||||
2 | Chagas disease (American trypanosomiasis) | |||||
3 | African trypanosomiasis | |||||
4 | Malaria | |||||
5 | Tuberculosis | |||||
6 | Measles | |||||
7 | Herpes simplex infection | |||||
NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
1 | BCR Signaling Pathway | |||||
Panther Pathway | [+] 1 Panther Pathways | + | ||||
1 | Toll receptor signaling pathway | |||||
Reactome | [+] 5 Reactome Pathways | + | ||||
1 | PI3K Cascade | |||||
2 | Trafficking and processing of endosomal TLR | |||||
3 | TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | |||||
4 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | |||||
5 | MyD88 dependent cascade initiated on endosome | |||||
WikiPathways | [+] 6 WikiPathways | + | ||||
1 | Toll-like receptor signaling pathway | |||||
2 | Toll-Like Receptors Cascades | |||||
3 | MyD88 dependent cascade initiated on endosome | |||||
4 | Trafficking and processing of endosomal TLR | |||||
5 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||||
6 | Regulation of toll-like receptor signaling pathway |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829. | |||||
REF 2 | ClinicalTrials.gov (NCT00810849) A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis. U.S. National Institutes of Health. | |||||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 5 | ClinicalTrials.gov (NCT02077868) Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment. U.S. National Institutes of Health. | |||||
REF 6 | ClinicalTrials.gov (NCT02384460) Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health. | |||||
REF 7 | ClinicalTrials.gov (NCT03445533) A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (ILLUMINATE-301). U.S. National Institutes of Health. | |||||
REF 8 | ClinicalTrials.gov (NCT01506362) Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis. U.S. National Institutes of Health. | |||||
REF 9 | ClinicalTrials.gov (NCT00277238) CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects. U.S.National Institutes of Health. | |||||
REF 10 | CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8. | |||||
REF 11 | Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). | |||||
REF 12 | ClinicalTrials.gov (NCT01622348) Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health. | |||||
REF 13 | ClinicalTrials.gov (NCT00936468) Safety, Tolerability and Immunogenicity of Fluzone With and Without JVRS-100 in Elderly Subjects. U.S. National Institutes of Health. | |||||
REF 14 | ClinicalTrials.gov (NCT03837756) Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN). U.S. National Institutes of Health. | |||||
REF 15 | Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. January 31, 2014. | |||||
REF 16 | ClinicalTrials.gov (NCT00537355) An Evaluation of the Efficacy and Safety of TOLAMBA for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber. U.S. National Institutes of Health. | |||||
REF 17 | Clinical pipeline report, company report or official report of SciClone. | |||||
REF 18 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025034) | |||||
REF 19 | ClinicalTrials.gov (NCT03684785) Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 20 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 21 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 22 | Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol. 2014 Jan;10(1):23-34. | |||||
REF 23 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 24 | ClinicalTrials.gov (NCT01743807) Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia. U.S. National Institutes of Health. | |||||
REF 25 | Clinical pipeline report, company report or official report of Oligovax SAS. | |||||
REF 26 | Targeting Toll-like receptors: emerging therapeutics Nat Rev Drug Discov. 2010 Apr;9(4):293-307. | |||||
REF 27 | Clinical pipeline report, company report or official report of Dynavax Technologies Corp. | |||||
REF 28 | Targeting Toll-like receptors: emerging therapeutics. Nat Rev Drug Discov. 2010 Apr;9(4):293-307. | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019204) | |||||
REF 30 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011959) | |||||
REF 31 | Clinical pipeline report, company report or official report of Idera Pharmaceuticals. | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027402) | |||||
REF 33 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. | |||||
REF 34 | Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. | |||||
REF 35 | Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020. | |||||
REF 36 | Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14. | |||||
REF 37 | Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51. | |||||
REF 38 | Company report (Iderapharma) | |||||
REF 39 | Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820. | |||||
REF 40 | Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096. | |||||
REF 41 | DOI: 10.1371/journal.pone.0087712 | |||||
REF 42 | Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291. | |||||
REF 43 | Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7. | |||||
REF 44 | Clinical pipeline report, company report or official report of dynavax. | |||||
REF 45 | Clinical pipeline report, company report or official report of Exicure. | |||||
REF 46 | Clinical pipeline report, company report or official report of Checkmate Pharmaceuticals. | |||||
REF 47 | Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. | |||||
REF 48 | Company report (Dynavax) | |||||
REF 49 | National Cancer Institute Drug Dictionary (drug id 662816). | |||||
REF 50 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). | |||||
REF 51 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019871) | |||||
REF 52 | Pfizer. Product Development Pipeline. March 31 2009. | |||||
REF 53 | CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther. 2007 Aug;7(8):1257-66. | |||||
REF 54 | Clinical pipeline report, company report or official report of Idera Pharmaceuticals. | |||||
REF 55 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | |||||
REF 56 | The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. Biochem Pharmacol. 2016 Jul 15;112:90-101. | |||||
REF 57 | Toll-like receptor 9 antagonism modulates astrocyte function and preserves proximal axons following spinal cord injury. Brain Behav Immun. 2019 Aug;80:328-343. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.